^
Association details:
| Biomarker: | HER-2 R647K |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Nerlynx (neratinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer
Excerpt:
We aimed to investigate the prevalence, clinicopathologic characteristics, and functional relevance of novel HER2 mutations in breast cancer....neratinib produced a strong inhibition of colony formation for all eight mutations, including K753E and L755S.
DOI:
10.1158/1078-0432.CCR-15-3036
